Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Molecular Pharmaceutics|January 30, 2019
Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinibAlexander Traxl, Severin Mairinger, Thomas Filip, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 12, 2013
Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro studyJens P Bankstahl, Marion Bankstahl, Kerstin Römermann, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2023
Positron Emission Tomography-Based Pharmacokinetic Analysis To Assess Renal Transporter-Mediated Drug-Drug Interactions of Antimicrobial DrugsIrene Hernández-Lozano, Severin Mairinger, Thomas Filip, et al.
Nuclear Medicine and Biology|December 24, 2022
Synthesis, radiolabeling, and preclinical in vivo evaluation of 68Ga-radiolabelled nanodiamondsThomas Wanek, Severin Mairinger, Marco Raabe, et al.
Molecular Pharmaceutics|January 16, 2024
Performance and Sensitivity of [99mTc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and LiverIrene Hernández-Lozano, Sarah Leterrier, Severin Mairinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2011
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancerThomas Wanek, Claudia Kuntner, Jens P Bankstahl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 18, 2009
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PETClaudia Kuntner, Jens P Bankstahl, Marion Bankstahl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2011
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptakeThorsten Fuereder, Thomas Wanek, Pamina Pflegerl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 16, 2019
In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistancePavitra Kannan, András Füredi, Sabina Dizdarevic, et al.
Nuclear Medicine and Biology|July 9, 2010
Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoateSeverin Mairinger, Oliver Langer, Claudia Kuntner, et al.
Pageof 9